Allergen Research Corporation Initiates Phase 2b Clinical Trial For Peanut Allergy Oral Immunotherapy (OIT)
2/27/2014 10:44:11 AM
SAN MATEO, Calif.--(BUSINESS WIRE)--Allergen Research Corporation (ARC), a privately held company developing desensitization treatment protocols and products for food allergies, today announced the start of its Phase 2b clinical trial for peanut allergy oral immunotherapy (OIT) with characterized peanut allergen (CPNA). The trial seeks to establish the safety and efficacy of OIT and CPNA as a prescribed treatment for individuals with peanut allergy to follow under the care of a trained and certified allergist.
Help employers find you! Check out all the jobs and post your resume.
comments powered by